Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) is anticipated to post its results before the market opens on Thursday, November 5th. Analysts expect Aptevo Therapeutics to post earnings of ($3.72) per share for the quarter.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) EPS for the quarter, beating analysts’ consensus estimates of ($6.02) by $0.71. On average, analysts expect Aptevo Therapeutics to post ($17.04) EPS for the current fiscal year and ($6.59) EPS for the next fiscal year.
Aptevo Therapeutics Stock Up 0.7%
Shares of NASDAQ APVO opened at $1.35 on Tuesday. Aptevo Therapeutics has a 12 month low of $1.25 and a 12 month high of $28.08. The business has a fifty day simple moving average of $1.83 and a 200-day simple moving average of $4.37.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.
Get Our Latest Stock Report on APVO
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions.
Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
